NASDAQ: PLYXPolaryx Therapeutics Inc Stock
$2.23+0.04 (+1.83%)
Updated Aug 4, 2026
PLYX Price
$2.23
Fair Value Price
$0.11
Market Cap
$105.58M
52 Week Low
$1.87
52 Week High
$48.91
P/E
N/A
P/B
42.43x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.41
Operating Cash Flow
N/A
Beta
1.04
Next Earnings
Aug 13, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PLYX Overview
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PLYX's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PLYX
Ranked#335 of 463
Ranked#335 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.07 | A | |
| $109.80 | A | |
| $8.19 | A |
Be the first to know about important PLYX news, forecast changes, insider trades & much more!
PLYX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PLYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PLYX ($2.23) is overvalued by 1,952.8% relative to our estimate of its Fair Value price of $0.11 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PLYX ($2.23) is not significantly undervalued (1,952.8%) relative to our estimate of its Fair Value price of $0.11 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PLYX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more PLYX due diligence checks available for Premium users.
Valuation
PLYX fair value
Fair Value of PLYX stock based on Discounted Cash Flow (DCF)
Price
$2.23
Fair Value
$0.11
Overvalued by
1,952.80%
PLYX ($2.23) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PLYX ($2.23) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PLYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
42.43x
Industry
5.28x
PLYX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PLYX's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
Assets to liabilities
Assets
$3.5M
Liabilities
$1.0M
Debt to equity
0.41
PLYX's short-term assets ($3.50M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PLYX's short-term assets ($3.50M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PLYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
$0.0
Financing
$0.0
PLYX vs Biotech Stocks
Polaryx Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.